Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial)

Inclusion Criteria: * 18-75 years old SARS CoV-2 Infection confirmed by positive virologic test realised in the 96 h before randomization * Beginning of COVID-19 symptoms \< 10 days at the time of randomization * Presence of symptom(s) of COVID-19 : fever (température \> or = 37,5°C) or respiratory sign(s) (cough, breathing discomfort) or recent anosmia * Presence of TDM/radiographic signs or pneumonia * Hospitalization out of ICU for COVID with: moderate clinical form (no oxygenotherapy) or non critical severe form (oxygenotherapy) Exclusion Criteria: * Absence of signed informed consent * SpO2 \< 90 % ambient air or \< 94 % with oxygenotherapy \> or = 3l/min * Need of oxygenotherapy \> 6 l/min or mechanical ventilation * Need of hospitalization in ICU * ALAT/ASAT \> 5 LSN * Renal failure (eGFR \< 40 ml/min ) or dialysis * Pregnancy or breastfeeding * Retinopathy * Known deficit in G6PD * Cardiac rythm / lengthening QT disorders * QT space lengthening on ECG with QTc \> 450 ms * Concomitant treatment :citalopram, escitalopram, hydroxyzine, domperidone, pipéraquine, anti-arhythmic class IA \& III, antidepressive drugs,..